|Day's Range||0.50 - 0.55|
|52 Week Range||0.26 - 1.16|
|PE Ratio (TTM)||1.05|
|Earnings Date||Mar 24, 2017 - Mar 27, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1.25|
Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has entered into an exclusive license and distribution agreement with Sayre Therapeutics for the development and commercialization of Tc 99m tilmanocept in India.
Navidea Biopharmaceuticals Inc. gets a new source of sales revenue with the European launch of the drug for which it sold North American rights in spring. SpePharm AG, a specialty pharmaceutical arm of Dutch distributor Norgine BV, started sales of Lymphoseek in the United Kingdom, Denmark and the Netherlands. SpePharm's exclusive sub-license applies to all 28 current EU member countries, and it is working to start sales in the rest.
Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that its European commercial partner, SpePharm AG, an affiliate of Norgine, B.V., launched LYMPHOSEEK® , originally developed by Navidea, in Denmark, the Netherlands and the UK.